INOVIO — Third Quarter 2026 Earnings Summary

INOVIO received accelerated FDA approval for VOCERYQ, the first FDA-approved DNA medicine, to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis. The company plans to make the therapy available for order and shipment within 60 days of the October 30, 2026 approval, with a full commercial launch scheduled for the first quarter of 2027. For the third quarter ended September 30, 2026, INOVIO reported a net loss of $49.2 million, driven largely by a $26.9 million non-cash loss on warrant liabilities, while research and development expenses decreased to $10.6 million. The company recently completed a public offering that generated $80.5 million in net proceeds to support the upcoming commercial launch of VOCERYQ.